Johann Gudjonsson, MD, PhD, FAAD

Video content above is prompted by the following:

Future Directions for GPP Management and Key Takeaways

In your opinion, what is spesolimab’s place in therapy when treating GPP?
a.	What unmet treatment needs remain, and what data would you like to see in the future?


What are some key takeaways or advice for other dermatologists who are managing patients with GPP?

Videos

Panelists discuss spesolimab’s place in therapy for treating  generalized pustular psoriasis (GPP), address remaining unmet treatment needs, and share the types of future data they would like to see, along with key takeaways and advice for dermatologists managing patients with GPP.


Utilizing Intravenous and Subcutaneous Formulations of Spesolimab

How do the results of EFFISAYIL-1 and -2 compare with the results you have seen with spesolimab in clinical practice?
a.	How do you discuss treatment expectations for spesolimab with your patients?


Discuss the utility of both an IV and SQ formulation of spesolimab. How are they similar and different, and how are both formulations used in the management of GPP?
a.	PK modeling (Hawkes, 2024)
b.	How do you ensure timely initiation of IV therapy and continuity of care when a patient is experiencing a flare?


Panelists compare the results of the EFFISAYIL-1 and 
-2 trials with real-world use of spesolimab; discuss treatment expectations with patients; and explore the similarities, differences, and management roles of intravenous (IV) and subcutaneous (SQ) formulations, with strategies for timely IV therapy initiation during flares.



Overview of Spesolimab for Management of GPP

Spesolimab, an IL-36R inhibitor, is now FDA-approved to treat GPP. Can you give a brief overview of spesolimab and the efficacy and safety evidence we have seen to date.
a.	EFFISAYIL-1—IV formulation (Bachelez, 2021)
b.	EFFISAYIL-2—SQ formulation (Morita, 2023)


Panelists provide an overview of spesolimab, an IL-36R inhibitor now FDA-approved for treating GPP, discussing the efficacy and safety data from the EFFISAYIL-1 trial (intravenous [IV] formulation) and the EFFISAYIL-2 trial (subcutaneous
[SQ] formulation).


Role of IL-36 in GPP Pathogenesis and Treatment

Describe the role of the IL-36 pathway in the pathogenesis of GPP and how IL-36 inhibition can play a role in disease management.

Panelists describe the role of the IL-36 pathway in the pathogenesis of  generalized pustular psoriasis (GPP) and discuss how IL-36 inhibition can be a key strategy in managing the disease.

Johann Gudjonsson, MD, PhD, FAAD

Articles